Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Income from Non-Controlling Interests: 2020-2025

Historic Income from Non-Controlling Interests for ImmunityBio (IBRX) over the last 6 years, with Sep 2025 value amounting to -$21,000.

  • ImmunityBio's Income from Non-Controlling Interests rose 8.70% to -$21,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$77,000, marking a year-over-year increase of 10.47%. This contributed to the annual value of -$81,000 for FY2024, which is 87.65% up from last year.
  • ImmunityBio's Income from Non-Controlling Interests amounted to -$21,000 in Q3 2025, which was down 10.53% from -$19,000 recorded in Q2 2025.
  • ImmunityBio's 5-year Income from Non-Controlling Interests high stood at -$17,000 for Q4 2024, and its period low was -$1.1 million during Q2 2021.
  • For the 3-year period, ImmunityBio's Income from Non-Controlling Interests averaged around -$72,455, with its median value being -$21,000 (2025).
  • Per our database at Business Quant, ImmunityBio's Income from Non-Controlling Interests tumbled by 122.88% in 2021 and then surged by 94.01% in 2024.
  • Quarterly analysis of 5 years shows ImmunityBio's Income from Non-Controlling Interests stood at -$294,000 in 2021, then surged by 62.24% to -$111,000 in 2022, then surged by 80.18% to -$22,000 in 2023, then increased by 22.73% to -$17,000 in 2024, then increased by 8.70% to -$21,000 in 2025.
  • Its last three reported values are -$21,000 in Q3 2025, -$19,000 for Q2 2025, and -$20,000 during Q1 2025.